When testing the combination therapy in RB-negative bladder cancer cell lines 639V and 647V, no positive effects on cell survival were observed, indicating again that this combination treatment requires an active RB-E2F-signaling pathway in the cells (Fig. 2h). Here, RB1 is linked to retinoblastoma.